Dorsey & Whitney Trust CO LLC trimmed its position in shares of CVS Health Corp (NYSE:CVS) by 14.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,194 shares of the pharmacy operator’s stock after selling 1,369 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in CVS Health were worth $509,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Wealthcare Advisory Partners LLC grew its holdings in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares in the last quarter. Wagner Wealth Management LLC purchased a new stake in CVS Health in the 4th quarter valued at $114,000. Avestar Capital LLC purchased a new stake in CVS Health in the 4th quarter valued at $122,000. Bedel Financial Consulting Inc. purchased a new stake in CVS Health in the 1st quarter valued at $125,000. Finally, Focused Wealth Management Inc grew its holdings in CVS Health by 90.5% in the 4th quarter. Focused Wealth Management Inc now owns 1,781 shares of the pharmacy operator’s stock valued at $129,000 after buying an additional 846 shares in the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.
CVS Health opened at $69.12 on Friday, according to MarketBeat. CVS Health Corp has a 12-month low of $60.14 and a 12-month high of $84.00. The company has a current ratio of 2.37, a quick ratio of 1.88 and a debt-to-equity ratio of 1.59. The stock has a market cap of $68.05 billion, a P/E ratio of 11.72, a PEG ratio of 0.93 and a beta of 1.00.
Several brokerages have issued reports on CVS. Loop Capital set a $68.00 target price on CVS Health and gave the company a “hold” rating in a report on Monday, May 7th. ValuEngine cut CVS Health from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Bank of America began coverage on CVS Health in a report on Tuesday, February 27th. They issued a “buy” rating and a $91.00 target price for the company. Leerink Swann set a $85.00 price target on CVS Health and gave the company a “buy” rating in a research note on Tuesday, April 10th. Finally, Mizuho set a $95.00 price target on CVS Health and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $86.27.
In other news, Director C David Brown II bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 4th. The shares were purchased at an average price of $61.99 per share, with a total value of $619,900.00. Following the purchase, the director now owns 101,252 shares in the company, valued at $6,276,611.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.53% of the stock is currently owned by corporate insiders.
About CVS Health
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.